ClinicalTrials.Veeva

Menu
Charité Universitätsmedizin Berlin | Deutsches Herzzentrum der Charité - Studienzentrale logo

Charité Universitätsmedizin Berlin | Deutsches Herzzentrum der Charité - Studienzentrale

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Baricitinib
LY3009104
Dexamethasone
Cytarabine
Pomalidomide
Dasatinib
LY3314814
Lanabecestat
Sodium Chloride
Paclitaxel

Parent organization

This site is a part of Charité Universitätsmedizin Berlin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

27 of 147 total trials

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) w...

Active, not recruiting
Indolent Systemic Mastocytosis
Drug: Placebo
Drug: Avapritinib

This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486...

Enrolling
ISM
Mastocytosis
Drug: Bezuclastinib Tablets (Formulation A)
Drug: Placebo Tablets

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Procedure: Liver Biopsy
Drug: MGL-3196

A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Pati...

Active, not recruiting
Gastric Cancer
GastroEsophageal Cancer
Drug: Tislelizumab 200mg
Drug: DKN-01 400mg

The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1...

Active, not recruiting
Hereditary Angioedema
Drug: STAR-0215

Primary objective: To estimate the efficacy of adjuvant nivolumab monotherapy in completely resected MCC patientsPrimary endpoint: Disease-free survi...

Active, not recruiting
Merkel Cell Carcinoma
Drug: Nivolumab

Atezolizumab is an engineered humanised monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1...

Active, not recruiting
Endometrial Cancer
Drug: Placebos
Drug: Atezolizumab

The goal of this first in human clinical trial is to test BI-1910 administered as single agent and in combination with pembrolizumab in subjects with...

Enrolling
Hepatocellular Carcinoma
Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: BI-1910

To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC). For more informa...

Active, not recruiting
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Drug: Eplontersen
Drug: Placebo
Locations recently updated

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants...

Enrolling
Relapsed Adult AML
Myelodysplastic Syndrome with Excess Blasts-2
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monothe...

Enrolling
Low-grade Glioma
Drug: Tovorafenib
Drug: Chemotherapeutic Agent

The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which tog...

Enrolling
Acute Myeloid Leukemia Refractory
Acute Myeloid Leukemia, in Relapse
Drug: Allo-RevCAR01-T
Drug: R-TM123

The main purpose of this study is to demonstrate that the growth of infants fed with the Test Formula is non-inferior those fed with the Control Form...

Not yet enrolling
Cow Milk Protein Allergy
Other: Control Formula
Other: Test Formula

This is a prospective, multi-center, open-label clinical trial intended to evaluate the safety and effectiveness of the MobiusHD® in patients with he...

Enrolling
Heart Failure With Reduced Ejection Fraction
Device: MobiusHD

A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in pati...

Enrolling
Acute-On-Chronic Liver Failure
Ascites
Other: SOC (Control Group)
Drug: VS-01 on top of SOC

Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb el...

Active, not recruiting
Newly Diagnosed Multiple Myeloma
Other: autologous stem cell transplant
Drug: Lenalidomide

The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy...

Enrolling
Non-small Cell Lung Cancer
Ovarian Cancer
Drug: TUB-040

The aim of the DigiNet project is to improve the treatment of patients with advanced non-small cell lung cancer (NSCLC) in Germany. The project promo...

Active, not recruiting
Non-small Cell Lung Cancer Stage IV
Other: DigiNet intervention

This clinical phase II study is designed to investigate the efficacy of intratumorally administered L19IL2/L19TNF in patients with injectable lesions...

Enrolling
Carcinoma, Basal Cell
Carcinoma, Cutaneous Squamous Cell
Drug: L19IL2 +L19TNF

Trial sponsors

Charité University Medicine Berlin logo
Lilly logo
U
CSL Behring logo
Pfizer logo
G
AstraZeneca logo
D
Daiichi Sankyo logo
U

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems